Literature DB >> 26793610

Everolimus-Eluting Stents Reduce Monocyte Expression of Toll-Like Receptor 4.

Mehriar Shokri1, Bahador Bagheri2, Alireza Garjani3, Bahram Sohrabi1, Afshin Habibzadeh4, Babak Kazemi1, Ali Akbar Movassaghpour5.   

Abstract

PURPOSE: Toll-like receptors (TLR) are well known components of the innate immune system. Among them, TLR4 is related to the inflammatory processes involved in atherosclerotic plaque formation. Our purpose was to compare the monocytic expression of TLR4 following implantation of drug-eluting (DES) and bare stents (BMS).
METHODS: In this study, patients with chronic stable angina undergoing elective percutaneous coronary intervention (PCI) in ShahidMadani Heart Hospital, Tabriz, Iran were included. Ninety-five patients receiving DES and 95 patients receiving BMS were selected between 2012 and 2014.Everolimus eluting stents were implanted for DES group. Both groups received similar medications and procedure. Blood samples were taken before PCI, 2 hours and 4 hours after termination of PCI. Expression of TLR4 on monocytes was measured using flowcytometry. Patients were matched for age, sex and coronary artery disease risk factors, but not for TLR4 expression rate before PCI.
RESULTS: A significant difference was seen between DES and BMS in TLR4 expression before (21.3±2.8% vs. 15.5±2.7%; P< 0.05) and four hours after PCI (30.1 ± 3.3% vs 39.2 ± 3.2%, P< 0.05). Due to the unmatched rate of TLR4+ expression before PCI, we measured the percentage of increase in TLR4 expression between groups. DES compared to BMS significantlycaused less increase in the TLR4 expression (50.23%±10.03% vs. 446.35%±70.58%, p<0.001).
CONCLUSION: Our findings suggest thateverolimuseluted from the stents can decrease PCI induced increase in the TLR4 expression on the surface of monocytes.

Entities:  

Keywords:  Inflammation; Percutaneous coronary intervention; Stent; TLR4

Year:  2015        PMID: 26793610      PMCID: PMC4708035          DOI: 10.15171/apb.2015.087

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  27 in total

Review 1.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

3.  Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention.

Authors:  Gerrit J Laarman; Maarten J Suttorp; Maurits T Dirksen; Loek van Heerebeek; Ferdinand Kiemeneij; Ton Slagboom; L Ron van der Wieken; Jan G P Tijssen; Benno J Rensing; Mark Patterson
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

4.  Monocyte expression of Toll-like receptor-4 in patients with stable angina undergoing percutanoeus coronary intervention.

Authors:  Bahador Bagheri; Bahram Sohrabi; Aliakbar Movassaghpur; Simin Mashayekhi; Afagh Garjani; Mehriar Shokri; Mohammad Noori; Alireza Garjani
Journal:  Iran J Immunol       Date:  2012-09       Impact factor: 1.603

5.  Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome.

Authors:  Heiko Methe; Jong-Oh Kim; Sieglinde Kofler; Michael Weis; Michael Nabauer; Joerg Koglin
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

Review 6.  Toll and Toll-like proteins: an ancient family of receptors signaling infection.

Authors:  J L Imler; J A Hoffmann
Journal:  Rev Immunogenet       Date:  2000

7.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

Review 8.  Inflammation and restenosis after percutaneous coronary interventions.

Authors:  Konstantinos Toutouzas; Antonio Colombo; Christodoulos Stefanadis
Journal:  Eur Heart J       Date:  2004-10       Impact factor: 29.983

Review 9.  Established risk factors and coronary artery disease: the Framingham Study.

Authors:  P W Wilson
Journal:  Am J Hypertens       Date:  1994-07       Impact factor: 2.689

10.  Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve.

Authors:  D Versteeg; I E Hoefer; A H Schoneveld; D P V de Kleijn; E Busser; C Strijder; M Emons; P R Stella; P A Doevendans; G Pasterkamp
Journal:  Heart       Date:  2007-08-08       Impact factor: 5.994

View more
  1 in total

1.  Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta.

Authors:  Yonghong Li; Junjie Guo; Haichu Yu; Xin Liu; Jingwei Zhou; Xianming Chu; Qingke Xu; Tingru Sun; Liang Peng; Xi Yang; Xilong Tang
Journal:  Physiol Res       Date:  2021-06-01       Impact factor: 2.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.